SCHEMBL6443532

SCHEMBL6443532

COc1ccc(Nc2ccccc2C(N)=O)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.72
KMT2A Q03164 4/20 0.72
PKM P14618 1/20 0.72
SIRT2 Q8IXJ6 9/20 0.71
MAPK10 P53779 4/20 0.63
MAPK9 P45984 1/20 0.63
MAPT P10636 3/20 0.58
KDM4E B2RXH2 1/20 0.58
ALDH1A1 P00352 1/20 0.58
GAA P10253 1/20 0.58
THRB P10828 1/20 0.58
HTT P42858 1/20 0.58
RECQL P46063 1/20 0.58
MMP14 P50281 1/20 0.58
RAB9A P51151 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
ALOX12 P18054 1/20 0.58
MAPK1 P28482 1/20 0.58
HSD17B10 Q99714 1/20 0.58
LMNA P02545 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30213377 0.86 AKR1C3 (0.72) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL355486 0.86 AKR1C3 (0.72) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL10935935 0.86 MEN1 (0.60) MEN1KMT2APKMSIRT2MAPT
SCHEMBL9409067 0.84 AKR1C3 (0.60) MEN1KMT2APKMSIRT2MAPT
SCHEMBL28357281 0.84 SIRT2 (0.75) SIRT2MAPK10KDM4ERECQLRAB9A
SCHEMBL10515711 0.83 MEN1 (0.65) MEN1KMT2APKMMAPTKDM4E
SCHEMBL10990122 0.83 MEN1 (0.61) MEN1KMT2APKMMAPK10MAPT
SCHEMBL15688476 0.82 SIRT2 (0.71) MEN1KMT2ASIRT2MAPTKDM4E
SCHEMBL294128 0.82 AKR1C3 (0.78)
SCHEMBL10983702 0.82 MEN1 (0.56) MEN1KMT2APKMSIRT2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107325019-B Aryl amine benzamide compound and N- aryl-aryl amine benzamide compound preparation method 石河子大学 2019-11-22 CN disclosed
CN-107325019-A The preparation method of aryl amine benzamide compound and N aryl aryl amine benzamide compounds 石河子大学 2017-11-07 CN disclosed
EP-2505198-A1 Compounds for use as therapeutic agents affecting p53 expression and/or activity Société Splicos (FR) 2012-10-03 EP disclosed
EP-1517897-A2 BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS Pfizer Products Inc. (US) 2005-03-30 EP disclosed
US-20040002524-A1 Benzimidazole compounds and their use as estrogen agonists/antagonists CHESWORTH RICHARD (US) 2004-01-01 US disclosed
WO-2004000817-A2 BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS ESTROGEN AGONISTS/ANTAGONISTS PFIZER PRODUCTS INC. (US) 2003-12-31 WO disclosed
US-4549016-A LIPOXYGENASE INHIBITORS, ANTIALLERGENS, ANTIASTHMA AGENTS STERLING DRUG INC. (US) 1985-10-22 US disclosed
US-4510139-A ANTYIALLERGENS; ASTHMA STERLING DRUG INC. (US) 1985-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002524-A1 Benzimidazole compounds and their use as estrogen agonists/antagonists ESR1, GPER1, ESR2 MEN1 4482/4885KMT2A 1738/4885PKM 1691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.